Congenital Adrenal Hyperplasia clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult subjects with classic CAH due to 21-hydroxylase deficiency. The study consists of a 6 month randomized, double blind, placebo-controlled period, followed by 1 year of treatment with crinecerfont. Duration of participation is approximately 20 months.
San Francisco, California and other locations